Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

HAS is accepting applications for inclusion in its 2024 work program

The French National Authority for Health (HAS) work program is defined each year according to public health priorities, following a procedure carried out in consultation with the Ministry of Health and Prevention and the national health insurance institution. It also considers requests from professional organizations and user associations.

On May 03, 2023, the HAS invited professional organizations and patient associations to submit their applications for inclusion of the topics in the HAS 2024 work program. These stakeholders must submit their applications to until July 7, 2023, using the provided application forms. An acknowledgment of receipt of the application is sent at the end of 2023 or the beginning of 2024.

This process is related only to requests to develop new/update existing HAS recommendations and not to the creation of novel procedure codes.

The applications will be analyzed, prioritized, and selected before being validated by the HAS Board and included in the work program (typically in the spring of next year).

See the details in French here

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.